Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Elamipretide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.60 |
| ▸ | NPY4R | P50391 | 12/20 | 0.63 |
| ▸ | NPY1R | P25929 | 7/20 | 0.63 |
| ▸ | NPY2R | P49146 | 5/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elamipretide SCHEMBL21627153 | 0.99 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| Elamipretide SCHEMBL18384105 | 0.99 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| Elamipretide SCHEMBL17374162 | 0.99 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| Elamipretide SCHEMBL23192356 | 0.99 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| Elamipretide SCHEMBL15028020 | 0.99 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| Elamipretide SCHEMBL23842427 | 0.99 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| Elamipretide SCHEMBL17374160 | 0.99 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| Elamipretide SCHEMBL19862103 | 0.99 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL18912830 | 0.98 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL26179137 | 0.97 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146997-A1 | Activation-dependent immune dysfunction traits enable identification of prodromal Parkinson's | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4731237-A1 | COMBINATION THERAPY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA | Stealth BioTherapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12540166-B2 | BNIP3 peptides for treatment of reperfusion injury | Bimyo GmbH (DE) | 2026-02-03 | — | — | US | disclosed |
| EP-3986401-B1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250319073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON’S DISEASE AND HTT PROTEINOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250302909-A1 | METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250295587-A1 | COMPLEX LIPID NANOPARTICLES ENCAPSULATING POLYPEPTIDES AND USES THEREOF | SAIL BIOMEDICINES, INC. | 2025-09-25 | — | — | US | disclosed |
| US-11420998-B2 | Aromatic-cationic peptides and methods for using same | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2022159756-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220220174-A1 | BNIP3 PEPTIDES FOR TREATMENT OF REPERFUSION INJURY | Bimyo GmbH (DE) | 2022-07-14 | — | — | US | disclosed |
| US-20220211654-A1 | MATERIALS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-07 | — | — | US | disclosed |
| US-20220152139-A1 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2022-05-19 | — | — | US | disclosed |
| CN-114466656-A | Peptidomimetic compounds (R) -2-amino-N- ((S) -1- (((S) -5-amino-1- (3-benzyl-1, 2, 4-oxadiazol-5-yl) pentyl) amino) -3- (4-hydroxy-2, 6-xylyl) -1-oxopropan-2-yl) -5-guanidinopentanamide in the treatment of neurodegenerative disorders | 康德生物医疗有限公司 | 2022-05-10 | — | — | CN | disclosed |
| EP-3986401-A1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-I-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Stealth BioTherapeutics Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3965747-A1 | MATERIALS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION | The Regents of the University of California (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966230-A1 | BNIP3 PEPTIDES FOR TREATMENT OF REPERFUSION INJURY | Bimyo GmbH (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540166-B2 | BNIP3 peptides for treatment of reperfusion injury | AIFM1, TFAM, MAVS | OPRM1 4564/4885NPY4R 1151/4885NPY1R 447/4885 |
| US-20250302909-A1 | METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | PDE6C, PDE6A, PDE6B | OPRM1 2338/4885NPY4R 306/4885NPY1R 231/4885 |
| US-20250319073-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUNTINGTON’S DISEASE AND HTT PROTEINOPATHIES | HTT, TTR, HYPK | OPRM1 1154/4885NPY4R 595/4885NPY1R 257/4885 |
| US-11420998-B2 | Aromatic-cationic peptides and methods for using same | ARG2, ARGLU1, ARG1 | OPRM1 1499/4885NPY4R 824/4885NPY1R 523/4885 |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | NLN, TARDBP, PARK7 | OPRM1 1348/4885NPY4R 2566/4885NPY1R 2391/4885 |
| US-20260146997-A1 | Activation-dependent immune dysfunction traits enable identification of prodromal Parkinson's | CD14, MAVS, LRRK2 | OPRM1 682/4885NPY4R 2953/4885NPY1R 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.